Ozempic and Wegovy are not injected the same way, and the operational steps for each come from the Instructions for Use (IFU) in your medication carton — not from any article. Ozempic uses a multi-dose pen that requires a new needle each time, a flow check before the first use of each pen, dose selection, and a six-second hold after the counter reaches zero. Wegovy uses a single-dose pen with a built-in needle, no priming, and a different completion signal. Following the wrong product’s procedure is the most common avoidable error. This article covers what the IFU does not explain well: site rotation, storage, travel, troubleshooting, and when to stop and call your clinician. It is educational and does not replace the IFU or the training your prescriber or pharmacist should provide. Advanced TRT Clinic is not affiliated with or endorsed by Novo Nordisk.
Before Your First Injection: What Should Already Have Happened
Self-injection is not meant to be learned from the internet. By the time you hold your first pen, three things should already be in place.
A demonstration. Your prescriber, a nurse, or your pharmacist should have shown you the device you were actually given and watched you handle it. Many pharmacies provide this at no cost and most patients never ask. If nobody has shown you, call before you inject, not after.
The Instructions for Use. Every carton contains a product-specific IFU approved by the FDA. It is the authoritative procedure for your device. If the carton has been discarded, the current version is available from the manufacturer and your pharmacist can print one. An IFU is occasionally revised when a device changes, which is one reason no article should be treated as a substitute.
A plan for problems. You should know who to contact if a pen malfunctions, if you miss a dose, or if a reaction develops — and whether that is your prescriber, the pharmacy, or an urgent care route.
This article explains the context around injection — why sites rotate, what storage failures look like, what common problems mean, and when a symptom warrants a call. It deliberately does not reproduce the step-by-step procedure. The IFU in your carton is the approved sequence for your specific device, it is updated when the device changes, and following it rather than a web page is the correct habit. Where this article and your IFU appear to differ, the IFU governs and your clinician decides.
Ozempic and Wegovy Are Not the Same Device
This is the most consequential thing to understand, and the most frequently confused. Both products contain semaglutide, both are weekly subcutaneous injections, and the brand names are often discussed together. The pens themselves work differently.
Two Devices, Two Procedures
Confirm which product you were dispensed before handling the pen
| OZEMPIC — MULTI-DOSE PEN | WEGOVY — SINGLE-DOSE PEN |
|
One pen holds several weekly doses A new needle is attached for every injection A flow check is required before the first use of each pen The dose is selected on a dial and shown in a counter After the counter reaches zero, the button is held for a further count The needle is removed and discarded after each use |
One pen holds exactly one dose The needle is built in and hidden — nothing to attach No flow check and no assembly The dose is preset — there is no dial Completion is signalled by the device itself, not a counter The entire pen is discarded after one use |
| Exact timings, hold counts and completion signals differ between products and are specified in each product’s own Instructions for Use. |
Figure 1. Device characteristics as described in current manufacturer materials. Devices are occasionally revised — your carton’s IFU reflects the version you were dispensed.
Two failure modes follow from this. A patient switched from Ozempic to Wegovy may look for a needle to attach and conclude the pen is defective. A patient moving the other way may not realise that a flow check and a hold count apply, and may deliver an incomplete dose without knowing it. Neither error is obvious at the time.
If your prescription changes between these products, treat the new device as unfamiliar even though the molecule is the same. Ask for a demonstration again. For the difference between the two products in indication, dosing and coverage, see our guide on Wegovy vs Ozempic: same drug, different use.
Neither product is manufactured in vial form. Semaglutide sold in a vial with a separate syringe — whether described as compounded, research-grade, or “not for human use” — is outside the legal supply chain. There is no way to verify identity, concentration, sterility, or dose, and dosing errors with a syringe have caused documented overdoses requiring emergency care.
Compounded semaglutide has not been available through standard legal channels since the FDA resolved the semaglutide shortage in February 2025. This article does not describe syringe technique, and Advanced TRT Clinic does not supply, source, or advise on the use of compounded or unapproved semaglutide. If you have been given a vial and told it is Ozempic or Wegovy, do not use it — contact a licensed clinician.
Where to Inject, and Why Rotation Matters
Three areas are approved for subcutaneous semaglutide: the abdomen, the front of the thigh, and the upper arm. All three are clinically equivalent in absorption for weekly semaglutide, so the choice is about comfort and reach rather than effect.
The abdomen is the most common choice because it has reliable subcutaneous tissue and is easy to see. The area immediately around the navel is avoided. The front of the thigh works well for patients who find the abdomen uncomfortable. The upper arm is awkward to self-administer and is usually the site of choice only when someone else is injecting.
Why rotation is not optional
Repeatedly injecting the same spot causes lipohypertrophy — a firm, rubbery thickening of the fat layer. It develops silently over months and matters for a practical reason: absorption from thickened tissue becomes unpredictable. The medication may be absorbed more slowly, less completely, or erratically, and because the change is gradual, patients often attribute the resulting loss of effect to the drug rather than to the site.
Rotating within an area is sufficient — you do not need to cycle between the abdomen, thigh and arm. Moving roughly an inch from the previous spot each week, and keeping an informal record of where you last injected, prevents the problem entirely. Skin that is tender, bruised, reddened, hardened, scarred or marked by stretch marks is skipped.
Weekly dosing works best when it is anchored to a fixed day rather than a fixed time, which makes it easier to remember and easier to shift if travel interferes. The site, by contrast, should change every week. Patients who do the opposite — same spot, drifting day — run into both lipohypertrophy and inconsistent timing. A note in your phone with the date and the site takes five seconds and solves both.
Storage, Travel, and What Ruins a Pen
Semaglutide is a peptide, and peptides are damaged by heat and by freezing. A pen that has been mishandled may look completely normal while delivering a degraded dose, which is why storage rules matter more than they appear to.
| Situation | What applies | Why it matters |
|---|---|---|
| Unopened storage | Refrigerated, 36–46°F (2–8°C), in the original carton | The carton protects from light as well as temperature |
| Freezing | Never. A frozen pen is discarded even after thawing | Freezing denatures the peptide irreversibly and invisibly |
| Room temperature | Permitted within a limited window and temperature range specified in your IFU | The allowance differs between products and between opened and unopened pens |
| Air travel | Carry-on only, in the original labelled carton, with a cool pack that does not freeze | Hold baggage reaches freezing temperatures; TSA permits medically necessary liquids and sharps when declared |
| Car or direct sun | Avoid entirely | A parked car exceeds the upper limit within minutes in warm weather |
| Appearance check | The liquid should be clear and colourless | Cloudiness, particles or discolouration mean the pen is not used — but normal appearance does not prove correct storage |
If a pen has been left out, frozen, or exposed to heat, do not reason your way to using it. Call the pharmacy. Replacement is routine and far cheaper than a month of unreliable therapy.
Common Problems and What They Actually Mean
Most questions that reach a clinic after a first injection fall into a small set. None of the situations below are emergencies, but several are commonly mishandled.
What Patients Ask After the First Injection
| USUALLY NORMAL | CALL FOR GUIDANCE | URGENT |
|
A small drop of blood at the site Mild redness lasting a day A brief sting during injection A tiny air bubble visible in the pen Slight bruising |
A missed or late dose Uncertainty whether a full dose was delivered A pen that was dropped or damaged A pen left out of refrigeration A firm lump forming at a repeated site |
Swelling of face, lips or throat Difficulty breathing Severe abdominal pain radiating to the back Spreading redness, warmth or pus at a site Signs of severe dehydration |
Figure 2. Educational triage summary only. Any symptom that concerns you warrants a call regardless of which column it appears in.
Air bubbles
A small bubble in a pen is not the hazard many people assume. The air-embolism risk that applies to intravenous injection does not translate to a subcutaneous injection of this volume. A large bubble can reduce the delivered amount, which is what the flow check on a multi-dose pen is designed to address. If a pen will not produce a flow check result as described in its IFU, that pen is not used.
A missed dose
Do not guess. Each product’s labeling specifies how long after a missed dose it may still be taken and what to do if that window has passed, and the rule is not the same for every product or situation. Doubling up to compensate is specifically not the answer — it increases gastrointestinal side effects without improving outcomes. Call your prescriber or pharmacist and follow the labeled instruction for your product.
Uncertainty about whether the dose went in
This is common on a first injection and the instinct is to re-dose. Do not. An incomplete dose is a minor problem; a double dose is a larger one. Note what happened, wait, and ask your clinician before the next scheduled injection.
Injection site reactions
Mild local redness or itching is reported with this class and usually resolves within a day. Spreading redness, warmth, increasing pain, or discharge suggests infection rather than a reaction and needs assessment. For the broader side effect picture of this drug class, see our guide to Ozempic side effects.
Sharps Disposal Is a Legal Requirement
Used needles and used single-dose pens are regulated sharps waste, not household rubbish. Placing them in a bin or recycling creates a documented injury risk for sanitation workers, and improper disposal of sharps violates state law in many jurisdictions.
An FDA-cleared sharps container is the correct destination. Where one is not immediately available, a heavy-duty plastic household container with a tight-fitting lid, kept upright and labelled, is an accepted interim measure — thin plastic, glass and anything that can be punctured or shatter are not.
Disposal of the full container is governed by local rules, which vary widely by state and sometimes by county. Pharmacy take-back, household hazardous waste collection, mail-back programmes and designated drop-off sites are the usual routes. Your pharmacist or state health department can tell you which applies where you live.
Use your product’s own IFU. Ozempic and Wegovy pens are operated differently. The procedure that applies is the one in the carton you were dispensed.
Never reuse or share a needle. Needles dull after one use, which increases tissue trauma, and sharing transmits bloodborne infection. This applies even within a household.
Rotate the site, keep the day. Repeated injection in one spot causes tissue changes that make absorption unpredictable, and the loss of effect is usually blamed on the drug.
When in doubt, do not re-dose. Call. An incomplete dose is a small problem; a double dose is a larger one.
When to Stop and Call
Separate from injection technique, certain symptoms require prompt medical attention regardless of how long you have been on therapy.
Severe abdominal pain, particularly pain radiating to the back and not relieved by position; swelling of the face, lips, tongue or throat; difficulty breathing; yellowing of the skin or eyes; a new lump in the neck, hoarseness or difficulty swallowing; vision changes; or signs of severe dehydration including inability to keep fluids down.
Semaglutide carries an FDA Boxed Warning for thyroid C-cell tumors. In rodent studies it caused dose-dependent thyroid C-cell tumors; whether this applies to humans is unknown. It is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Other labeled risks include pancreatitis, gallbladder disease, diabetic retinopathy complications in type 2 diabetes, acute kidney injury and gastrointestinal adverse reactions.
Injection technique is the smallest part of succeeding on this therapy. Dose escalation, tolerability management, nutrition and monitoring account for far more of the outcome, and all of them belong with a clinician rather than an article. For how supervised semaglutide therapy is structured in practice, see our guide on semaglutide for weight management, and for the wider context of this drug class, our complete GLP-1 class overview.
Get a Physician Evaluation for GLP-1 Therapy
Advanced TRT Clinic provides administrative and technology services that connect patients with independent licensed clinicians through Beluga Health, P.A., who provide all clinical evaluation, treatment selection, prior authorization support, and ongoing monitoring, including device training and technique review where appropriate. Advanced TRT Clinic is not a pharmacy, does not fill prescriptions, does not supply or source compounded or unapproved medications, and is not affiliated with, endorsed by, or a distributor for Novo Nordisk or Eli Lilly. No specific clinical outcome, insurance approval, or medication availability is guaranteed. All prescribing decisions are made by independent licensed clinicians based on individual patient assessment, within their scope of practice and applicable state law. Availability varies by state.
